Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
First Trust NYSE Arca Biotechnology UCITS ETF (FBTU.L)
About this ETF
This passively managed investment vehicle aims to broadly replicate the price movements and income generated by the NYSE Arca Biotechnology IndexSM, before any fees and expenses are deducted. The underlying "Index" is constructed using a modified equal-weighting methodology and tracks the performance of a diverse group of companies within the biotechnology sector, primarily those engaged in leveraging biological processes to develop products or provide specialized services.
Price
Top 10 holdings
| Veracyte, Inc. VCYT | 4.00% |
| Axsome Therapeutics, Inc. AXSM | 3.95% |
| Corcept Therapeutics Incorporated CORT | 3.84% |
| Arrowhead Pharmaceuticals, Inc. ARWR | 3.81% |
| Neurocrine Biosciences, Inc. NBIX | 3.80% |
| Illumina, Inc. ILMN | 3.79% |
| Krystal Biotech, Inc. KRYS | 3.76% |
| Bruker Corporation BRKR | 3.74% |
| Biogen Inc. BIIB | 3.62% |
| Alkermes Plc ALKS | 3.61% |
Sector mix
Price chart
Returns
| 1 month | +9.05% |
| 3 months | +23.06% |
| 6 months | +16.67% |
| Year to date | +18.36% |
| 1 year | +49.31% |
| 3 years (ann.) | +17.15% |
| 5 years (ann.) | +7.49% |
| 10 years (ann.) | — |
Risk profile
| Volatility (1y, ann.) | 24.01% |
| Sharpe (1y) | 1.79 |
| Sharpe (3y) | 0.86 |
| Sortino (1y) | 2.99 |
| Max drawdown (1y) | -14.30% |
| Max drawdown (5y) | -29.97% |
| Max drawdown (full) | -33.73% |
| Beta vs S&P 500 (1y) | 0.62 |
| Correlation vs S&P 500 (1y) | 0.35 |
Technical outlook as of 2026-07-13
The Monte Carlo cone is drawn on the price chart above (Forecast overlay); RSI, MACD and the rest of the oscillators live in its indicator panels.
Full holdings
| Constituent | ISIN | Market value | Weight |
|---|---|---|---|
| Loading… | |||
Sector breakdown
Geographic exposure
Cost vs. peers
Comparison universe: 6,948 funds of the same asset class.
Cost impact calculator
Dividend history
Accumulating share class Income is reinvested inside the fund instead of being paid out. (inferred from the absence of distributions)
No distributions on record — accumulating share classes reinvest income instead of paying it out.
ESG profile
Benchmark: average of 4,066 funds of the same asset class with derived ESG data.
Similar ETFs
| Fund | TER | AUM (USD) | Yield (TTM) | Return 1y | Sharpe 1y |
|---|---|---|---|---|---|
| Vanguard Total Stock Market ETF VTI | 0.03% | 2.30T | 1.05% | +19.93% | 1.48 |
| Vanguard S&P 500 ETF VOO | 0.03% | 1.70T | 1.07% | +19.68% | 1.49 |
| iShares Core S&P 500 ETF IVV | 0.03% | 894.38B | 1.09% | +19.68% | 1.49 |
| State Street SPDR S&P 500 ETF SPY | 0.09% | 789.23B | 1.00% | +19.71% | 1.49 |
| SPDR S&P 500 ETF Trust 1557.T | 0.09% | 789.09B | 0.49% | +37.54% | 2.26 |
| State Street SPDR S&P 500 ETF SPY.AX | 0.09% | 788.13B | 1.00% | +11.84% | 1.13 |
| Vanguard Total International Stock ETF VXUS | 0.05% | 652.30B | 2.61% | +20.58% | 1.21 |
| Invesco QQQ Trust, Series 1 QQQ | 0.18% | 481.14B | 0.43% | +28.14% | 1.43 |
| Vanguard Growth ETF VUG | 0.03% | 393.80B | 0.39% | +16.85% | 0.99 |
| Vanguard FTSE Developed Markets ETF VEA | 0.03% | 317.30B | 2.60% | +21.64% | 1.23 |
Cheaper alternatives
No fund of the class reaches 60% portfolio overlap — showing the cheapest funds of the class instead.
| Fund | TER | AUM (USD) | Overlap |
|---|---|---|---|
| Vanguard Small-Cap ETF VB | 0.03% | 182.70B | 2.6% |
| Invesco QQQ Trust, Series 1 QQQ | 0.18% | 481.14B | 2.6% |
| Vanguard Value ETF VTV | 0.03% | 245.00B | 1.7% |
| Vanguard Total Stock Market ETF VTI | 0.03% | 2.30T | 1.1% |
| State Street SPDR Portfolio S&P 500 ETF SPYM | 0.02% | 159.32B | 0.9% |
